Confocal Scanning Laser Ophthalmoscopy (CSLO) is a sophisticated imaging technique used in ophthalmology to capture detailed images of the retina and optic nerve head. It employs a confocal scanning laser system to produce high-resolution, three-dimensional images of the eye’s interior.
This technology is valuable in diagnosing and managing various eye conditions, including glaucoma, macular degeneration, diabetic retinopathy, and optic nerve disorders. It is also used in research settings for studying the structure and function of the eye.
The IOL Master is used to measure various parameters of the eye, particularly for calculating the power of intraocular lenses (IOLs) used in cataract and refractive surgery. IOL Master stands for Intraocular Lens Master. Unlike ultrasound biometry, which requires contact with the eye, the IOL Master is non-invasive and does not require any physical contact with the eye’s surface. The IOL Master is also proficient at measuring challenging eyes, such as in patients who have a staphyoma or silicone oil-filled eyes following retinal surgery. It measures the length of the eye to the nearest 0.01mm.
Optical Coherence Tomography (OCT) is a non-invasive imaging technique. It provides high-resolution, cross-sectional images of biological tissues with micrometer-scale resolution. OCT works on the principle of interferometry, which involves measuring the echo time delay and magnitude of backscattered or reflected light. OCT is commonly used to visualize the layers of the retina, optic nerve head, and cornea. It aids in the diagnosis and management of various eye conditions, including macular degeneration, diabetic retinopathy, glaucoma, and retinal detachment. OCT allows clinicians to assess the thickness and integrity of retinal layers, detect pathological changes, and monitor disease progression.
The term “diode pulse laser” refers to a type of laser that uses diode technology to generate pulsed laser beams. Diode lasers are semiconductor lasers that emit light when an electric current passes through them. These lasers are known for their compact size, efficiency, and versatility in various applications.
Solitaire is a full-featured, portable green laser with a true continuous wave laser beam and real-time energy control, offering consistently better performance in the treatment of retinal disease.
The attached laser slit lamp has a 10-degree convergence angle viewing path and high-resolution optics to provide optimal illumination of the fundus and superior peripheral viewing. True Spot™ Optics offers uniform, sharp-edge top-hat beam on the retina with low power density at the cornea.
Developed by Lumibird Medical, this machine enables ophthalmologists to perform the full range of anterior and posterior YAG laser procedures, including Laser Floater Treatment (LFT) or Laser Vitreolysis. Additional treatment modalities include Premium Capsulotomy and Iridotomy. The Yag Laser provides an enhanced visualisation of both the anterior and posterior vitreous. It’s technology that provides a stable and titratable red reflex across the entire working diameter within the pupil, that creates the highest degree of contract, edge definition and detail shadowing for posterior capsule and throughout the vitreous.
Selective Laser Trabeculoplasty (SLT) is a laser procedure used to treat glaucoma and reduce eye (intraocular) pressure by improving fluid outflow through drainage pores located within the trabecular meshwork. SLT uses short pulses of low-energy light to improve drainage of aqueous fluid in order to lower eye pressure. SLT is typically employed as a primary or adjunctive treatment when medications alone are insufficient to control IOP or when patients experience side effects from medications.
During SLT, a specially designed laser is used to apply low-energy, short-duration laser pulses to the trabecular meshwork, which is the drainage system of the eye located near the base of the cornea. The laser energy selectively targets pigmented cells within the trabecular meshwork while sparing adjacent tissues, such as the cornea and iris.
The laser energy induces a biological response within the trabecular meshwork, leading to remodelling and increased outflow of aqueous humor from the eye. This helps to improve the drainage of fluid and subsequently lowers intraocular pressure.
SLT is considered a minimally invasive procedure because it does not involve surgical incisions or removal of tissue. It is typically performed as an outpatient procedure in the ophthalmologist’s office and does not require general anaesthesia.
SLT can be repeated if necessary, allowing for additional IOP reduction or maintenance of IOP control over time. Repeat treatments are often performed when the effects of the initial SLT procedure diminish or if further IOP reduction is required.
SLT has a favourable safety profile compared to traditional trabeculoplasty procedures, such as argon laser trabeculoplasty (ALT). Because SLT selectively targets pigmented cells, it is associated with minimal thermal damage to surrounding tissues and a lower risk of complications such as scarring or inflammation.
SLT can be used as an adjunctive therapy in combination with glaucoma medications or as a primary treatment option for patients with newly diagnosed open-angle glaucoma.
The Humphrey Visual Field Analyzer (HVF) is a sophisticated diagnostic instrument used in ophthalmology to assess a patient’s visual field. It’s particularly valuable in diagnosing and monitoring conditions that affect peripheral vision, such as glaucoma, optic nerve diseases, and certain neurological disorders.
The HVF conducts perimetry testing, which involves measuring the sensitivity of a patient’s visual field at various points within their central and peripheral vision. During the test, the patient focuses on a central fixation target while lights of varying intensity are presented in different locations within their visual field. The test takes approximately 5-8 minutes per eye
The HVF performs automated threshold testing, where the intensity of the stimulus lights is adjusted automatically based on the patient’s responses. This allows for precise determination of the patient’s visual field sensitivity threshold at each test location.
The HVF offers different testing patterns, including the 24-2, 30-2, and 10-2 grids, which vary in the number of test locations and their spacing across the visual field. These patterns allow for comprehensive assessment of both central and peripheral vision.
The HVF software includes tools for tracking changes in the patient’s visual field over time. By comparing the results of multiple tests, clinicians can monitor disease progression, evaluate the effectiveness of treatment, and make informed decisions about patient management.
The HVF provides reliability indices, such as fixation loss, false-positive errors, and false-negative errors, to assess the quality of the patient’s responses during testing. These indices help ensure the accuracy and validity of the results.
The Centurion Vision System is an advanced platform for phacoemulsification, which is a modern technique for cataract surgery. Developed by Alcon, a global leader in eye care, the Centurion system offers advanced features and technology to enhance surgical precision, efficiency, and safety during cataract removal procedures.
The included ACTIVE SENTRY® facilitates operating at lower, more physiological IOP, potentially supporting a comfortable procedure for patients. ACTIVE SENTRY® technology helps reduce post-occlusion surge and maintain stability in the anterior chamber by adjusting for IOP fluctuations.
The Centurion system incorporates active fluidics technology, which helps maintain stable intraocular pressure (IOP) during surgery. This technology dynamically adjusts fluidics parameters in response to changes in the eye, optimizing chamber stability and maintaining a consistent surgical environment.
The system delivers ultrasound energy efficiently and precisely, allowing surgeons to emulsify the cataract with minimal trauma to surrounding tissues. This balanced energy delivery helps reduce the risk of corneal burns and endothelial damage.
The Centurion system features an intelligent phacoemulsification algorithm that adjusts power levels and vacuum settings in real-time based on feedback from sensors and the surgical environment. This helps optimize cutting efficiency while minimizing the risk of complications such as capsule rupture or iris trauma.
The system offers improved fluidic control and management, including advanced occlusion sensing technology to detect occlusions and maintain stable IOP. This helps prevent surge and allows for smoother surgical maneuvers.
The Centurion system is designed to accommodate a wide range of surgical techniques and preferences, including traditional phacoemulsification, micro-incision cataract surgery (MICS), and femtosecond laser-assisted cataract surgery (FLACS). Surgeons can customize settings and parameters to suit their individual preferences and patient needs.
Cyclodiode laser is a type of laser treatment used in the management of glaucoma, particularly in cases where traditional methods like medications, trabeculectomy, or tube shunts have failed or are deemed inappropriate. It’s also considered for patients who are not good candidates for other surgical procedures due to anatomical or medical reasons.
The ciliary body is the part of the eye responsible for producing fluid that fills the eye (aqueous humor). In certain types of glaucoma, reducing the production of aqueous humor can help lower intraocular pressure (IOP). Cyclodiode laser therapy involves using a diode laser to deliver energy to the ciliary body, selectively destroying some of its tissue. This reduces the production of aqueous humor, thus lowering IOP.
Cyclodiode laser therapy is typically performed as an outpatient procedure, often in an office setting. It involves numbing the eye with local anesthesia and then applying the laser energy to the ciliary body using a specialized lens.
The laser settings can be adjusted to target different portions of the ciliary body and to achieve the desired level of IOP reduction. The treatment can be titrated based on the patient’s response and the severity of their glaucoma.
Cyclodiode laser therapy is often considered in cases of refractory glaucoma, where other treatments have been ineffective or are not feasible. It may be used as a primary treatment or as an adjunct to other therapies, depending on the individual patient’s needs and the severity of their glaucoma.
Cyclodiode laser therapy can provide long-term reduction in IOP for many patients. However, periodic follow-up visits with an ophthalmologist are necessary to monitor IOP levels and assess the need for additional treatments or adjustments to therapy.